Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.

Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 clinical data of nex-z for ATTR-CM on November 10 at AHA 2025; previously ...

Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...

Korro Bio saw its stock reach all-time lows on disappointing data for its lead pipeline candidate, while Intellia Therapeutics saw analyst downgrades on safety concerns despite releasing positive data ...

In biotech, success often begins in the lab — and for CRISPR pioneers, every clinical trial feels like a moonshot.

Intellia Therapeutics NTLA reported third-quarter 2025 loss of 92 cents per share (including one-time expenses of change in ...

Intellia Therapeutics faces a pivotal moment as the biotech firm prepares to release third-quarter financial results. While the company is scheduled to present Q3 figures on Thursday, investor ...

Intellia had already paused dosing in trials of nex-z in transthyretin amyloidosis after the patient was hospitalized due to a serious adverse event.

The biggest stories of the day delivered to your inbox.

The Vivo V70 has appeared on Geekbench with the Snapdragon 7 Gen 4, 8GB RAM and Android 16, hinting at an early 2026 launch.

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo! Finance) implies a significant 131% upside from its current levels. And ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best gene-editing stocks to buy according to hedge funds.